ADAPTIVE BIOTECHNOLOGIES CORPORATION Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent of -0.60% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther · last filed 2026-02-26
- ADAPTIVE BIOTECHNOLOGIES CORPORATION effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2025 was -0.60%.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2024 was -0.10%.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2023 was -0.10%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent 12 month |
|---|---|
| 2025-12-31 | -0.60% 10-K · filed 2026-02-26 |
| 2024-12-31 | -0.10% 10-K · filed 2026-02-26 |
| 2023-12-31 | -0.10% 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |